The growing interest on polymeric delivery systems for pulmonary administration of drugs anticipates a more direct and efficient treatment of diseases such as tuberculosis (TB) that uses the pulmonary route as the natural route of infection. Polymeric microparticles or nano-in-microparticles offer target delivery of drugs to the lungs and the potential to control and sustain drug release within TB infected macrophages improving the efficiency of the anti-TB treatment and reducing side effects. In a dry powder form these inhalable delivery systems have increased stability and prolonged storage time without requiring refrigeration, besides being cost-effective and patient convenient.
in a spectrum of disease with different phenotypes and clinical manifestations [1] . It is estimated that approximately one-third of the world population has contacted with Mtb and part of this population is likely latently infected [2] . Although these individuals do not show signs or symptoms of TB, as the bacteria proliferation is under immune control, they have a 10% increased risk of progressing into active TB during their life time being therefore important reservoirs for transmission [3] .
The current anti-TB therapy protocols comprise of a six-month combination course of rifampicin (R), isoniazid (I), pyrazinamide (Z) and ethambutol (E), which are first-line anti-TB drugs. All four drugs are taken during the first two months of the treatment following a period of four months where only rifampicin and isoniazid are taken. Although the success rate of this regimen has been estimated to be over 85% [2] , the full length of treatment is crucial for the effective and complete eradication of the pathogen. However, the incorrect use of anti-TB drugs or the use of ineffective drug formulations such as single drug regimen, poor quality medicines or inappropriate storage conditions and premature treatment interruption due to the long duration of the therapeutic regimen and the associated toxic side effects, lead to drug resistance [2] .
Treatment for drug resistant strains, which include rifampicin-resistant TB (RR-TB), multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) is longer (up to 2 years) and requires more expensive and more toxic drugs with treatment success rates lower than 54% [2] .
Therefore, in addition to classical drug discovery strategies, new approaches are urgently needed to get a faster, more efficient and less harmful treatment. In this regard, the development of novel therapies aiming at pulmonary delivery and drug targeting to the site of infection could be a promising solution to allow a sustainable and controlled release of medicines with therapeutic action, while decreasing the dosage and frequency of conventional chemotherapy and minimizing side effects. Moreover, these approaches may lead to a higher efficiency of the treatment and to a higher patient compliance, minimizing the risk of therapy failure and the development of drug resistant strains.
Delivery of anti-tuberculosis drugs to the lungs

Advantages of the pulmonary route
Despite the natural barriers to prevent invasion of unwanted airborne particles or living entities, such as airway geometry, humidity, mucociliary clearance and resident populations of macrophages, the lungs are constantly challenged with infectious agents, including Mtb, which make these air-filled organs an attractive target for drug delivery strategies as it provides direct access to the infection site. Delivery systems for TB treatment through the pulmonary route present advantages when compared to the conventional oral and injectable routes. These include drug delivery directly to the infected area, increasing local drug concentration which will impact in bacterial burden and reduce the systemic dosage of the drug [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Additionally, inhalable systems avoid unwanted side effects often caused by drug metabolism in the gastrointestinal tract before the drug reaches the systemic circulation [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Unlike the injectable route, inhalation is a pain free and self-administrable delivery means favoring patient convenience and compliance to the treatment.
Particulate carriers as inhalable delivery systems
Pure drug formulations are typically burst released in the lungs and rapidly undergo unspecific distribution [5, [14] [15] [16] [17] [18] . In order to achieve a more efficient solution, therapeutic agents can be formulated into particulate carrier systems such as microparticles, nanoparticles, liposomes, micelles or dendrimers. Such systems allow protection of drugs from direct contact with the lung tissue, avoiding early degradation, preclude rapid clearance from the body and assist the control and sustain release of drugs over long periods of time. Particulate carriers also reduce drug toxicity, circumvent undesirable physicochemical properties of the drugs (e.g. low water solubility) and improve drug uptake by macrophages [19] .
In recent years the advantages of inhalable particulate carrier systems have been allied to the benefits of dry powder formulations to be delivered by dry powder inhalers (DPIs) for an improved drug delivery system. Dry powder formulations have improved stability as a result of its dry form, do not require refrigeration and allow longer storage periods. Formulations are often combined with pharmaceutically suitable excipients such as lactose, leucine, mannitol or trehalose to improve processing and aerodynamic properties [20, 21] . DPIs are propellant free, portable, easy to use and cost-effective devices. Moreover, DPIs are activated by the inspiration effort of patients, allowing a rapid and higher dose administration and a more efficient pulmonary drug deposition [22, 23] . Thus, DPIs are currently considered the most convenient and suitable alternative for inhaling anti-TB drugs [24] .
Design and features of inhalable particulate systems
Medicinal particles are designed and developed so their deposition in the respiratory tract can be predicted rather precisely (Fig. 1) . The Fig. 1 . Schematic representation of the particle deposition within the upper or lower airways considering their dimensions and the type of carrier systems used for their delivery.
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behavior of inhaled particles and their deposition depend of several parameters including particle dimensions, density, shape, composition, concentration, surface properties such as particle charge and the breathing pattern (air flow) of the individual [13, 25] . The aerodynamic diameter is an important parameter affecting the pulmonary trajectory and depends on both particle dimension and density. Particles with an aerodynamic diameter in the range 1-5 μm are deposited in the lower airways, which is a desirable location for anti-TB drugs [13, [26] [27] [28] . On the other hand, particles larger than 5 μm undergo deposition in the upper regions, such as the nasopharynx and they are consequently swallowed, while particles smaller than 1 μm are likely to be exhaled or retained in the alveoli if transported by a carrier system [13, 26, 29] . After reaching the lower airways, particulate systems are likely to be either phagocytized by alveolar macrophages, adhere to the lung tissue or enter the blood circulation via lung vascular tree. Another potential destination is the entrapment of these particles within the granulomas which are compact and organized aggregates of immune cells where Mtb persists [30, 31] .
Types of microparticulate dry powder systems
Liposomes, micelles and polymeric particles have been developed as inhalable dry powder particulate systems aiming at anti-TB drug delivery strategies. Liposomes and micelles studies were reviewed elsewhere [32, 33] . Polymeric particles offer great opportunities in target drug delivery and controlled and sustained release of drugs. The possibility of surface modification of polymeric particles can give rise to systems with a great diversity of physicochemical properties and, if desired, favor a more efficient targeting approach [34] . Additionally, the production of polymeric particles is considerably more cost-effective than lipidic systems.
Polymeric particles include microparticles and nano-in-microparticles and these can further be divided into nanocomposites (also referred as nano-embedded microparticles) and porous nanoaggregate particles (PNAPs) (Fig. 2) . Nano-in-microparticle systems have been developed to utilize nanoparticulate systems, often exhaled from the lungs, into successful inhalable drug carrier systems (Fig. 1) . In nanocomposites, drug loaded nanoparticles are incorporated in a micronized sugar matrix (e.g. lactose, mannitol, leucine, maltodextrin) to form micro-scaled particles of 1-5 μm. These nanocomposites can then be decomposed into nanoparticles in the lower airways, since the sugar moiety is soluble in the lung lining fluid. On the other hand, PNAPs consist of spherical nanoaggregates at the micron-size level that also redisperse into the elementary nanoparticles in the lung lining fluid.
A considerable focus has been given to synthetic polymers poly (lactide-co-glycolide) (PLGA) and polylactide (PLA) due to their biocompatible and biodegradable properties, non-toxicity [35] [36] [37] and to the ability to encapsulate hydrophobic anti-TB drugs. Synthetic polymers also benefit from high purity products and batch-to-batch uniformity. However, more recently, the trend for dry powder production has been shifted towards the use of natural polymers such as chitosan, gelatin or guar gum due to their abundance and availability in nature, cost effectiveness and the fact that these raw materials require a minimal use of organic solvents to be processed. Also, combinations of polymers have been tested to merge properties of the polymers involved in order to obtain more efficient delivery systems.
Techniques used to develop polymeric microparticulate dry powders
A brief explanation on the most common production techniques to prepare inhalable polymeric drug delivery microparticulate and nanoin-microparticulate systems is described in Table 1. The techniques  presented in this table have shown to produce carrier systems with suitable aerodynamic diameters using a wide range of synthetic and natural based polymers.
Emulsion followed by solvent evaporation is commonly used to produce microparticles, in particular PLGA microparticles, however these are produced with a relatively wide size distribution [38] . Makino et al. have used this technique with a Shirasu porous glass (SPG) membrane to formulate microparticles with lower size dispersion [39, 40] . In order to overcome the low yield of this process, a premix membrane emulsification method was used to prepare monodispersed PLGA microparticles [41, 42] . Alternatively to SPG membrane emulsification, an adjuvant strategy based on glass beads facilitated stirring, improved the homogeneity of PLGA microparticles produced by the emulsion/solvent evaporation method [43] . Although emulsion/solvent evaporation is often used to produce anti-TB drug loaded microparticles, it is labor intensive and not practicable for large production, which can limit translational strategies into therapies.
Inhalable microparticles and nano-in-microparticles were successfully obtained using the spray-drying (SD) technique [38, [44] [45] [46] , the most used technique for production of inhalable dry powders for anti-TB delivery. SD is a simple, fast and versatile technique that can be used with different spray nozzles. For instance, rifampicin dihydrate microcrystals were coated with PLGA and/or PLA by SD with a three-fluid spray nozzle producing core-shell microcapsules with the appropriate aerodynamic properties to reach the alveoli and with controlled release properties not achieved by using only rifampicin dihydrate microcrystals [14, 15] . Due to the existence of three independent channels, one for the core (drug), one for the shell (polymer) and the other for the 
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Materials Science & Engineering C xxx (xxxx) xxx-xxx atomizing gas, the process can be done in a single step. Nanocomposites containing rifampicin-PLGA nanoparticles and mannitol have also been prepared in a one-step approach using a fourfluid nozzle spray drier [53] . In this technique two liquid and two gas passages allowed the drug and the carrier to be prepared in different solvents avoiding the limitations associated to using a common solvent as in the traditional two fluid spray-drier.
Spray-drying can also be combined with techniques such as antisolvent precipitation and ionotropic gelation that are oriented to nanoparticle production, to fabricate nano-in-microparticulate systems. Inhalable guar gum nanoparticles were prepared using the precipitation technique with ethanol as anti-solvent [50] . Chitosan and alginate nanoparticles have been prepared by the ionotropic gelation, a method based on the complexation between oppositely charged species namely chitosan and tripolyphosphate anion or calcium cation and alginate [51, 52, 54] . The physical cross-linking by electrostatic interactions avoids toxic reagents used in the chemical cross-linking such as glutaraldeyde.
The supercritical technique has also been proposed for the production of inhalable polymeric microparticles. Patomchaiviwat et al. prepared rifampicin loaded PLA microparticles, in a size range suitable for lower airways deposition, using a supercritical anti-solvent process [49] . Supercritical anti-solvent is a quite recent and barely explored technique for anti-TB drug delivery. Although it is a single step process this technology is expensive and labor intensive and requires deeper investigation to assess its full potential for anti-TB drug delivery.
Carrier systems oriented for macrophage targeting
Phagocytosis of drug carrier systems by macrophages especially by infected macrophages is a very interesting approach leading to the internalization of these systems, and to an intracellular influx of the drug in the phagosome, where the bacilli reside, which could result in a more efficient anti-TB approach.
Among the physical properties, the size of the particulate carrier system is one of the most important characteristics affecting up-take via phagocytosis (Fig. 3) [55] .
Phagocytosis ranged particles (1-6 μm) enter the macrophage and can potentially deliver larger amounts of anti-TB drugs directly to the infection than oral or injected drug doses [56] . Particle shape also plays an important role in the up-take process as the local shape determines the initial contact with macrophages and their phagocytic fate [57] . Using shape-switching particles it was shown that elliptical disks have potential to mitigate phagocytosis, however when they switched their shape into spheres they were internalized by macrophages [58] . In relation to surface charge an increase up-take was observed when PLGA microparticles were coated with cationic polymer polyethylenimine relative to uncoated ones [43] . Furthermore, harder and non-porous particles are more efficiently taken up than soft and porous particles and hydrophobic and insoluble particles are more easily opsonized and this fact increases the probability of recognition by alveolar macrophages [55] . The chemical composition of the particle is also a significant feature for macrophage response. PLGA microparticles prepared with different proportions of lactide and glycolide and with different PLGA molecular weights result in different interactions with alveolar macrophages [59] . The presence of mannose moiety in the structure of polymers such as guar gum and mannan results in higher up-take by macrophages [51, 60, 61] . The carrier surface can be functionalized to incorporate ligands that target macrophage surface receptors in a process that is known as active targeting. Mannosylated gelatin microparticles have been developed to target macrophage mannose membrane receptor [62] . Other ligands including carbohydrate binding receptors such as galactose, β-glucan, N-acetylglycosamine and folic acid have been explored for macrophage targeting aiming at a wide range of diseases [63] . However, their potential towards therapeutic TB strategies requires further investigation.
Emerging inhalable polymeric dry powders
The main outcomes on recent works on dry powder microparticles and nano-in-microparticles for anti-TB drug delivery envisioning the improvement of inhalable administration of therapeutic drugs are compiled in Tables 2 and 3 , respectively. The production of inhalable dry powder polymeric microparticles for pulmonary anti-TB drug delivery began with rifampicin loaded PLGA (R-PLGA) microparticles prepared by O'Hara and Hickey in 2000 [38] . In the meanwhile, the role of PLGA properties such as molecular weight and monomer composition have been studied to more accurately predict the loading efficiency and release rate of rifampicin [39] . Moreover, particles size [40] , polymer content [65] , pH of release medium [39] and presence of pulmonary surfactants in the release medium [29, 48] have also been assessed for their influence in rifampicin release profile. R-PLGA microparticles have shown to be effectively phagocytosed by NR8383 macrophage cells and exerted a more potent bactericidal effect on Mycobacterium bovis Bacillus Calmette-Guérin infected NR8383 macrophage cells than a rifampicin solution [39, 47, 56, [81] [82] [83] [84] [85] . These results were supported with in vivo studies, where the insufflation of R-PLGA microparticles to Wistar rats lead to 10 times greater amount of rifampicin in alveolar macrophages than a rifampicin insufflated powder [84] . Using Sprague-Dawley rats infected with Mtb Kurono strain as a model, intratracheal administration of R-PLGA microparticles was shown to be more efficient in killing the intracellular bacilli and on the prevention of granuloma formation in the lungs than a rifampicin powder [85] . The efficacy of inhalable R-PLGA microparticles was also assessed in Mtb (H37Rv)-infected guinea pigs by insufflation and/or nebulization into the lungs [18, 86] . The bacterial burden and lung damage was significantly reduced in the presence of the microparticles and the effect of a single dose of R-PLGA microparticles was found to be comparable to that after treatment for 20 consecutive days with micronized rifampicin suspensions [87] .
Polylactide (PLA)
Inhalable PLA microparticles were developed to incorporate both rifampicin and isoniazid as a promising carrier for anti-TB drug delivery [4] . These microparticles were up-taken by J774 murine macrophages and led to higher intracellular drug concentrations in comparison with equivalent amounts of drugs given in the culture medium. Mtb H37Ra infected J774 macrophages responded to rifampicin and isoniazid loaded PLA microparticles with a classical activation macrophages response not observed with drug solutions alone [45] . Additionally, rifampicin and isoniazid loaded PLA micropaticles administered to rats via intratracheal instillation and inhalation resulted in higher intracellular drug concentrations than oral and intracardiac injection delivery of soluble drugs [4] . These studies confirm that phagocytosis of particulate polymeric drug carriers results in the delivery of higher amounts of drugs to TB infected macrophages than those obtained from diffusive uptake of drugs dissolved in body fluids.
In another work by Muttil et al. rifabutin instead of rifampicin was loaded in inhalable PLA microparticles mainly because rifampicin is incompatible with isoniazid in organic solutions [5] . These rifabutin and isoniazid loaded PLA microparticles when administered to mice by inhalation or intra-tracheal instillation targeted macrophages as intracellular drug concentrations were found to be about 20 higher than serum concentrations. This approach also resulted in higher drug concentrations in macrophages than oral, intra-cardiac injection and even intra-tracheal instillation of free drug solutions [5, 88, 89] . Inhalation of rifabutin and isoniazid loaded PLA microparticles by Rhesus macaques also evidenced an efficient targeting of alveolar macrophages and lung tissue sparing non-target sites such as blood, liver and kidneys from the toxic drugs [90] . The ability of rifabutin and isoniazid loaded PLA microparticles to sustain higher levels of drugs in the cytosol of macrophages and for longer periods in comparison with soluble drugs highlight their efficacy in stimulating innate biological responses evoking a bactericidal action including induction of free radicals, changes in membrane potential and apoptosis [91] [92] [93] .
Poly-caprolactone (PCL)
Although not so explored in inhaled anti-TB dry powders as PLGA and PLA, PCL has also been used to design microparticles suitable for pulmonary drug delivery [16, 70] . In vitro and in vivo studies have shown that inhalable isoniazid loaded PCL (I-PCL) microparticles lead to a higher uptake as well as to a higher generation of mycobactericidal nitric oxide (NO) relative to isoniazid microparticles. This could be due to the hydrophobic nature of PCL favoring alveolar macrophages uptake and is an indication of the superior efficacy of PCL microparticles in comparison with isoniazid microparticles. As expected, intratracheal administration of I-PCL microparticles to rats lead to higher isoniazid accumulation in the lungs and less systemic drug availability and less hepatotoxicity effects over oral isoniazid administration. Thus, I-PCL microparticles prepared as inhalable dry powders may improve TB treatment efficacy and reduce hepatotoxicity which in turn will lead to a reduced period of treatment and improvement of patient compliance.
Hydroxyl propyl methyl cellulose (HPMC)
HPMC has been used as drug carrier [71, 94] and inhalable dry Table 3 Inhalable polymeric nano-in-microparticulate dry powders for TB treatment. 58.4 ± 6.1 85% drug release in 24 h followed by sustained release [51] (continued on next page)
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powder formulations have been prepared with rifampicin [71] and ethionamide [72] , an anti-TB drug used in the treatment of MDR-TB. Although these studies suggest the suitability of HPMC formulations for reaching the lower airways, in vitro and in vivo studies are still needed to validate their application in TB treatment.
Chitosan
The mucoadhesive properties of chitosan are related to its cationic charge and makes chitosan more likely to adhere to the lungs and prolong drug release [95, 96] . Moreover, chitosan particles are able to interact with the mannose receptors of macrophages, which results in increased phagocytosis [97] . Chitosan microparticles have been formulated with several anti-TB drugs including rifampicin [71, 73, 74] , rifabutin [74] , isoniazid [75, 76] , ofloxacin [60] and ethionamide [72] for pulmonary delivery. Cross-linked isoniazid loaded chitosan microparticles allowed a more sustained isoniazid release with 50% release in 6 h in comparison to non-crosslinked microparticles with over 50% released in 1 h [76] . Both non-and crosslinked microparticles can be of interest for TB treatment because in the first phase of the treatment, which is more intense, non-crosslinked microparticles may rapidly release isoniazid into the alveoli whereas cross-linked microparticles can be used in a second phase of the treatment (maintenance phase). Also the mucoadhesive properties of both non-and cross-linked chitosan microparticles were confirmed in vitro and in vivo, which can increase their time of residence in the lungs after inhalation. Moreover, both chitosan microparticles showed some toxic effect on murine peritoneal macrophages (J-774.1) which was microparticle concentration dependent (0.01-1 mg/mL) but no toxic effect on alveolar macrophages (AMJ2-C11). The activation of AMJ2-C11 cells with chitosan microparticles resulted in increased amounts of inflammatory cytokines: TNF-α, IL-1β, IL-6 in AMJ2-C11 cells in comparison to free isoniazid solubilized in culture medium.
As for other chitosan drug loaded microparticles, chitosan microparticles loaded with rifampicin and rifabutin showed to be less toxic to the lungs than free drug administration [74] .
Gelatin
Although gelatin is not so deeply studied for pulmonary delivery, gelatin microparticles loaded with isoniazid have been produced to actively target alveolar macrophages [62] . As macrophages hold mannose membrane receptors, mannosylated gelatin microparticles exhibited significantly higher intracellular concentration of isoniazid than the non-mannosylated. Additionally, intratracheal administration of isoniazid loaded mannosylated gelatin microparticles to rats allowed achieving isoniazid therapeutic concentration in plasma. These results suggest the potential application of macrophage targeting in TB treatment that should be more deeply investigated.
Hyaluronic acid (HA)
Hyaluronic acid (HA) has also been explored for the development of microparticles for anti-TB pulmonary drug delivery. HA is a versatile polysaccharide involved in the assembly of the extracellular matrix (ECM) of numerous native tissues and has been applied in multiple clinical procedures. Ofloxacin loaded HA (Ofx-HA) microparticles have shown good aerosolization efficiency when combined with lactose [6] . Ofx-HA microparticles uptake by the alveolar macrophage cell line (RAW 264.7) lead to higher ofloxacin concentration than from ofloxacin microparticles or from an ofloxacin solution. Moreover, intratracheal administration of Ofx-HA microparticles to rats seems to be much more effective than intravenous or oral administration of an ofloxacin solution and intratracheal administration of ofloxacin microparticles for the treatment of TB.
Locust Bean Gum (LBG)
LBG is a polysaccharide composed of galactose and mannose units with potential application for macrophage targeting. Inhalable 60.8 ± 5.1 65% drug release in 24 h followed by sustained release [51] Legend: E: ethambutol; FPF: fine particle fraction (fraction of the total inhaled dose that reaches the stages corresponding to the cut-off diameter of 5 μm); HPMC: hydroxy propyl methyl cellulose; I: isoniazid; MMAD:
mass median aerodynamic diameter; PLGA: poly(lactide-co-glycolide); PNAPs: porous nanoaggregate particles; PNAP40: PNAPs containing 40% nanoparticles; PNAP80: PNAPs containing 80% nanoparticles; R: rifampicin; SD: spray-drying; SE: solvent evaporation. f Nanoparticles were prepared by emulsion/solvent evaporation and PNAPs by spray-drying.
g PNAPs were prepared with 40% R-PLGA nanoparticles (PNAP40) and 80% R-PLGA nanoparticles (PNAP80) both with leucine.
h Nanoparticles prepared by anti-solvent precipitation were mixed with excipients and resultant mixture was spray-dried.
i Drug loaded alginate/CaCl 2 nanoparticles prepared by ionotropic gelation were mixed with excipients and resultant mixture was spray-dried.
j Chitosan/tripolyphosphate nanoparticles prepared by ionotropic gelation were mixed with excipients and spray-dried.
k Chitosan/tripolyphosphate nanoparticles prepared by ionotropic gelation were freeze-dried with lactose as cryoprotectant and mixed with lactose in the ratio 95:5.
l Optimum formulation: CHI/TPP 6:1 + lactose + leucine and weight ratio drug:excipient 10:90.
m Nanoparticles of drug were obtained by nanospray drying and were physically mixed with microsized chitosan carrier prepared by spray drying.
n Chitosan/tripolyphosphate nanoparticles prepared by ionotropic gelation were mixed with a guar gum solution and excipients and the resultant mixture was spray-dried.
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isoniazid and rifabutin loaded LBG microparticles were taken up by two macrophage cell lines: human macrophage-differentiated THP-1 cells and rat alveolar macrophages (NR 8383 cells) with high percentages of phagocytosis [61] . In another study by the same group LBG microparticles loaded with both drugs, isoniazid and rifabutin, thus meeting WHO requirements concerning combined TB therapy [77] .
Combination of polymers
The idea of merging the advantageous properties of different polymers led to the development of microparticulate systems that result from the combination of polymers such as chitosan and ethyl cellulose [78] . Ethyl cellulose, which is a hydrophobic matrix carrier, was used for encapsulating and sustained release of the hydrophobic drug rifabutin, while chitosan was envisioned to provide bio-adhesion to the microparticles promoting pulmonary retention of the delivery system. The produced microparticles showed sustained release due to crosslinking with genipin and intratracheal administration to rats lead to prolonged pulmonary retention, thus maintaining drug concentrations at therapeutic level for at least 24 days.
Poly-lysine is a cationic polymer and the toxicity associated to its high charge density and high molecular weight restricts its use as a drug carrier system. Tiwari et al. coupled a low molecular weight lysine polymer with mannose in order to reduce the toxicity of the carrier system, having also a synergistic effect on the uptake by macrophages [62] . The lysine polymer was also conjugated with alginate to reduce the toxicity of the system, improve drug loading efficiency and for a sustained and controlled drug release. This mannosylated lysine conjugated to alginate (m-LS-co-ALG) natural based carrier system was used for pulmonary delivery of isoniazid. m-LS-co-ALG microparticles have no significant toxic effects in rat alveolar macrophages up to a concentration as high as 20 mg/mL. Isonizaid loaded m-LS-co-ALG microparticles, intratracheally administered to rats, were effectively up-taken by alveolar macrophages and prolonged the presence of isoniazid in the blood.
The most studied polymers for microparticle production for inhalable delivery are PLGA and PLA although natural polymers such as chitosan have gained great interest in recent years due to their availability, cost-effectiveness and resemblance to biopolymers from living tissues. Despite chitosan being an attractive candidate for inhalable drug delivery other natural sources should be considered and their applicability explored. Biopolymers as collagen or chondroitin sulfate are natural materials used for particle fabrication in biomedical applications that could be transposed and investigated for TB approaches.
Different polymers have shown promising results in the design and loading of anti-TB drugs in clinical use. The incorporation of anti-TB drugs in polymer based carriers often increases the drug solubility, allows the protection of the drug before reaching the target site and allows modulating the release profile of the drugs assisting a sustained release.
With very few exceptions, studies report microparticulate systems incorporating first line drugs. This approach is quite useful to improve treatments efficiency by reducing the drug dosage (without prejudice to their effectiveness), reduction of systemic toxicity, reducing the regimen period and thus contributing to the eradication of the disease. Nevertheless, the development of polymeric dry powder delivery systems is also envisioned to contribute to anti-TB therapies when the treatment fails. Second line drugs as capreomycin and ofloxacin, which are typically more toxic that first line drugs, could have their dosage reduced and the parental administration replaced by the pulmonary route favoring stability, storage and shelf life. This approach would also favor patient compliance to the treatment and likely increase the success rate in drug resistant-TB strategies.
Polymeric nano-in-microparticles
3.2.1. Poly(lactide-co-glycolide) (PLGA)
Rifampicin loaded PLGA nanocomposites have been produced by Tomoda et al. to be used as an inhalation system [20, 21] . The influence of the excipient, size of primary nanoparticles, weight ratio nanoparticle:excipient and inlet temperature of the spray dryer on the aerodynamic and decomposition properties of the nanocomposites were investigated. Nanoparticles with dimensions of 200 nm and 400 nm, combined with trehalose at the inlet temperatures of 70°C and 80°C, respectively, were considered the most promising ones for pulmonary delivery. These results were independent from the weight ratio nanoparticle:excipient.
Rifampicin loaded PLGA nanocomposites prepared with mannitol (R-PLGA/MAN) were readily dispersed in culture medium and dissociate to nanoparticles which are not so efficiently in vitro up-taken by NR8383 cells (13.5%) as micro-sized rifampicin loaded PLGA particles (47.1%) [53] . Conversely, intra-tracheal administration of R-PLGA/ MAN nanocomposites to rats lead to a higher rifampicin uptake (about 9.3% after 4 h) by alveolar macrophages in comparison with R-PLGA and R/MAN microparticles which was explained by the difficulty to clear the nanoparticles from the lungs.
Intratracheal insufflation of rifampicin-PLGA PNAPs formulations to guinea pigs led to a prolonged presence of rifampicin in the lungs up to 8 h whereas insufflated rifampicin porous particles or rifampicin given intravenously or orally showed low or no levels of rifampicin in the lungs [28] .
Hydroxy propyl methyl cellulose (HPMC)
PNAPs of HPMC loaded with rifampicin and isoniazid were prepared with mannitol and leucine to improve yield and aerodynamic properties of the powders [98] . 24 h after insufflation of the developed PNAPs in rats, approximately 25% of drug was still in the lungs while in the case of plain drug administration no drug was detected. Moreover, organ distribution studies showed a lower level of drug from the developed PNAPs in the liver and kidney in comparison with plain drug due to the controlled drug release from the PNAPs formulations.
Alginate
Alginate nanocomposites have been developed for pulmonary delivery of rifampicin and isoniazid [52] . The minimum inhibitory concentration (MIC) of rifampicin (0.2 ± 0.01 μg/mL) and isoniazid (0.1 ± 0.01 μg/mL) loaded alginate nanocomposites against Mtb was approximately 3-4 times lower than that of free rifampicin (0.5 ± 0.01 μg/mL) and isoniazid (0.4 ± 0.01 μg/mL) solutions. Developed formulations insufflated to mice could be detected in the lungs for up to 8 h ensuring a localized and controlled drug delivery and exhibited a higher rate and extent of drug uptake by lungs than by liver, spleen and kidney.
Chitosan
Chitosan nanocomposites have been prepared for anti-TB pulmonary drug delivery. Inhalable rifampicin loaded chitosan nanocomposites have shown negligible in vitro toxicity on murine J774 macrophage cells [99] . Inhalation of the developed formulation by rats lead to a higher maximum drug concentration and a higher residence time in the lungs (up to 24 h) in comparison with a rifampicin commercial powder, explained by the sustained release of rifampicin from the developed formulation. Moreover, only mild changes were found in the pathology of treated lungs from the developed formulation unlike a commercial rifampicin solution given orally that showed severe toxicity.
Guar gum
The presence of the mannose moiety in guar gum imparts a great affinity towards macrophage mannan receptors increasing macrophage cells up-take [51] . Rifampicin and Isoniazid loaded guar gum PNAPs insufflated to rats revealed a greater amount of drug in the lungs in comparison with the liver and kidneys [50] . Moreover, unlike plain drug administration, about 15% of the drugs from the developed formulations were still detected in the lungs after 24 h, which was ascribed M.S. Miranda et al.
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to the mucoadhesive properties of guar gum and the ability to control the release of the drugs from the developed systems.
Mannan
Mannan is a linear polysaccharide of mannose subunits which could favor specific recognition by macrophages and potentiate phagocytosis. Inhalable rifampicin and isoniazid loaded mannan nanocomposites have demonstrated an excellent uptake by J-774 macrophage cells and a MIC about 15 times lower than those of rifampicin and isoniazid solutions [51] . However, when insufflated to Mtb infected mice they exhibited a low lung residence time due to their intrinsic solubility.
Combination of polymers
Goyal et al. prepared nanocomposites made of different polymers namely chitosan, guar gum, mannan and guar gum coated chitosan nanocomposites [51] . Guar gum coated chitosan nanocomposites were shown to be the most promising for pulmonary anti-TB drug delivery. Guar gum coated rifampicin and isoniazid loaded chitosan nanocomposites insufflated to Mtb infected mice showed a prolonged residence of the drug in the lungs thereby improving the therapeutics utility and resulted in almost 5-fold reduction of the number of bacilli as compared to the untreated control group 45 days post administration [51] .
Although the nano-in-microparticles produced are promising for drug delivery these particles are still less studied than microparticles for TB treatment. The anti-TB drug loading in nano-in-microparticles is increased over microparticles due to a greater surface area/volume ratio of nanoparticles. Nano-in-microparticles re-disperse into the elementary nanoparticles in the lung lining fluid and due to their dimensions they are not cleared as fast as the microparticles, which may lead to an increased presence in the lungs leading to a higher drug up-take [53] . However, as referred in Section 2.5, the production of nano-inmicroparticles relies on a combination of techniques and a multi-step production, which is labor intensive and difficult to scale up.
Overall, polymeric systems either in the form of microparticles or as nano-in-microparticles have been developed with improved functionalities to efficiently transport and release the drug to the lung alveoli and to target a resident population of macrophages. Independently of the polymer systems and associated specificities, the advantage of using polymeric dry powders as drug loading microparticulate system over direct drug administration to the lungs is evident for pulmonary delivery and towards the treatment of TB.
It is important, however, to establish standardized models, both in vitro and in vivo, that enable to more accurately compare the effectiveness and therapeutic potential of the drug loaded particulate systems developed. It is critical to study these systems in models that mimic the transport along the human airways, considering real therapeutic dosages given to human patients and the challenges involved in the mechanisms for drug release and particle uptake in macrophages in order to validate their application in clinics.
Targeting host cell responses
Mtb has co-evolved with humans for thousands of years and has developed several strategies to prevent elimination by its host. Hostmediated responses, such as activation of protective inflammatory mediators, including cytokines and chemokines that induce natural microbicidal pathways and recruit white blood cells to the infection site, may provide an efficient mean to effectively eliminate Mtb and targeting host responses has been recently explored for TB treatment. However, a considerable disadvantage over bacteria-oriented approaches is the toxicity to the host cells, which can be overcome to a certain extent using carrier systems.
Verma et al. explored alveolar macrophage response to NO using PLGA microparticles containing NO donors (isosorbide mononitrate, sodium nitroprusside or diethylenetriamine nitric oxide adduct) [102] .
NO is known to possess mycobactericidal properties and indeed it is one of the most important macrophage microbicidal mechanisms. The addition of anti-TB drugs rifabutin and isoniazid further increase the efficiency of the developed system [103] . Gupta et al. produced inhalable PLGA microparticles for targeting rapamycin, which is an inducer of autophagy, to alveolar macrophages [104] . The PLGA microparticles containing rapamycin were less toxic to host cells and more effective in inducing the clearing of intracellular Mtb, as compared to rapamycin in the free form. The efficiency of this system was also found to increase in conjunction with inhalable rifabutin and isoniazid [105] . Other systems of inhalable particles containing nitazoxanide, which has moderate mycobactericidal activity and is also an inducer of autophagy in mammalian cells, were incorporated alone or in combination with rifabutin and isoniazid agents [106] . The combination of these drugs incorporated in the polymeric microparticles cleared Mtb H37Rv from lungs and spleen of infected mice and restored tissue architecture in higher extent than rifabutin-isoniazid particles.
Magnetic nanoparticles for anti-TB drug therapies
Magnetic nanoparticles (MNPs) have shown potential for a wide range of biomedical applications, including biosensing, imaging and targeted drug delivery, as MNPs can be manipulated under the influence of a magnetic field [107, 108] . MNPs have already been approved for clinical use as contrast agents in magnetic resonance imaging (MRI) allowing the diagnostic of several diseases. Additionally, MNPs can be oriented and concentrated towards a given tissue location via an external magnetic field actuation allowing a more efficient treatment and minimizing side effects. Magnetized aerosols comprising superparamagnetic iron oxide nanoparticles (SPIONs) have been studied for pulmonary delivery of drugs and genes to treat diseases of the deeper airways [109, 110] . These nanomagnetosols have shown potential to be in vivo controlled and spatially guided in the lungs using an external magnetic gradient field.
Despite the promising outcomes of MNPs for pulmonary delivery applications, few studies refer their use in inhalable dry powders for TB treatment strategies. MNPs can be incorporated within microparticulate systems and be part of a sophisticated imaging and guiding system for pulmonary drug delivery purposes. Tewes et al. fabricated SPIONsloaded Trojan microparticles for targeting bacterial infectious pulmonary foci upon loading with the appropriate drug [111] . This preliminary study showed that the developed microparticles have good aerodynamic properties and their deposition was found to be highly sensitive to the actuation of an external magnetic field. Moreover, the drug release profile can be modulated according to the treatment requirements with the application of an external stationary or alternating magnetic fields, contributing for improved treatment efficiency [112] . In a recent paper gelatin-based microparticles containing SPIONs were proposed as inhalable dry-powder carriers for a candidate anti-TB drug to be released inside alveolar macrophages [113] . The actuation of an external alternating magnetic field was shown to remotely trigger and modulate the anti-TB drug release, which could contribute for improved strategies for TB treatment.
Conclusions and future perspectives
Tuberculosis is a worldwide disseminated disease with potential to be treated and ultimately eradicated. Current therapeutic regimens show limitations than can be overcome with more sophisticated and oriented approaches, such as using inhalable polymeric dry powders for anti-TB drug delivery. These systems are quite versatile and growing evidence suggests that they are also more efficient in the drug targeting macrophages than oral or injected drug administration and even drug free inhalation. Moreover, dry powders show promising outcomes for the treatment of lung diseases and with impact in the quality of life of patients. The fact that they are easily stored, cost-effective and simple to administer are attractive features for up-scaling and commercialization. Magnetic particles can add clinical significance to the system as a valuable tool to guide the system to a given location and, simultaneously provide a non-invasive real-time monitoring system during the follow-up of patients after drug administration.
Moreover, the ability to target phagocytosed bacilli or the cells involved in Mtb clearance is a considerable advantage to be deeper investigated aiming at personalized strategies, considering each patient individual needs and orient the most suitable treatment not only in terms of drug selection but also targeting a specific location (either alveoli niche, alveoli macrophage, Mtb bacilli or the granuloma) to better suit the patient needs.
In the future, pulmonary delivery systems can eventually combine the administration of one or multiple pharmaceutical agents to induce different yet synergistic responses for instance, microbiocidal effect over Mtb and simultaneously target alveoli macrophages towards a more effective and shorter treatment regimen.
The challenge in upcoming years also resides in fine tuning inhalable dry powder carriers focusing on their multifactorial nature and final application, accompanying the progress of new anti-TB formulations to meet individual needs with simple yet efficient drug delivery systems to be routinely used in clinical therapies.
